Are We Overtreating DCIS?

Slideshow

With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on lung cancer
A panel of 4 experts on multiple myeloma
A panel of 4 experts on lung cancer
Video 8 - "Closing Thoughts on the Future of NSCLC"
Video 7 - "Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC "
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Related Content
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

May 17th 2024
Article
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

May 13th 2024
Podcast

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

May 17th 2024
Article

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.

FDA Approves Tarlatamab After Progression on Chemotherapy in ES-SCLC

May 16th 2024
Article

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.

53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ

53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ

May 16th 2024
Article